| خلاصه مقاله | ABSTRACT
Background and aims: Artificial Intelligence (AI) and radiomics have emerged as transformative tools in the diagnosis, treatment planning, and prognosis assessment of head and neck cancers (HNCs). Leveraging machine learning (ML) and deep learning algorithms, AI facilitates the extraction and analysis of high-dimensional radiomic features from medical imaging, enabling precise tumor characterization and personalized therapeutic strategies. The integration of AI in radiomics has the potential to enhance early tumor detection, predict treatment response, and minimize radiation toxicity, ultimately improving patient outcomes. This study aims to provide a comprehensive analysis of AI-driven radiomics in HNC care, with a particular focus on its application in multidisciplinary tumor board decision-making. By examining the opportunities, underlying mechanics, and challenges associated with AI in radiomics, this review seeks to highlight its role in advancing clinical decision support systems and optimizing cancer management. Method: A systematic review was conducted using databases such as PubMed, Scopus, and Google Scholar to identify relevant studies published between 2020 and 2025. Keywords included 'AI in head and neck cancer,' 'radiomics in oncology,' 'machine learning in cancer imaging,' and 'AI-driven precision oncology.' After screening 75 articles, 20 were selected based on relevance and methodological rigor. The review analyzed AI-driven radiomics applications in HNC, focusing on tumor segmentation, prognostic modeling, and treatment optimization.
Results: AI-powered radiomics has demonstrated significant potential in HNC by refining tumor detection accuracy, enabling automated segmentation, and enhancing predictive modeling for disease progression and therapeutic response. Machine learning algorithms analyze imaging biomarkers to guide clinical decision-making, reducing reliance on invasive procedures. Despite these advancements, challenges persist, including data heterogeneity, standardization issues, and ethical concerns related to patient privacy and algorithmic bias. Moreover, the lack of large-scale, annotated datasets and regulatory hurdles impede the widespread clinical adoption of AI-driven radiomics. Conclusion: AI and radiomics offer groundbreaking opportunities for precision medicine in HNC management. However, overcoming technical, ethical, and regulatory challenges is crucial to ensuring safe and effective implementation. Collaborative efforts between researchers, clinicians, and regulatory bodies are essential to harness AI’s full potential in revolutionizing HNC care. |